Shots:

• The P-IIa (VEGA) PoC study evaluating guselkumab + golimumab as induction therapy vs guselkumab or golimumab alone for maintenance in a ratio (1:1:1) in patients with mod. to sev. active UC
• The results showed clinical remission rate (47.9%) over guselkumab (31.0%) or golimumab alone (20.8%) @38wks.; symptomatic remission (69% vs 59.7%)
• In an exploratory analysis, endoscopic improvement, symptomatic & endoscopic remission, histologic remission, and composite histologic-endoscopic EPs were also assessed @38wks., the combination therapy followed by guselkumab/guselkumab alone/golimumab alone had AE rates (63.4%/64.8%/76.4%) & infection rates (31.0%/23.9%/31.9%), 13.1% discontinued treatment before a final dose of the study intervention

Ref: PRNewswire | Image: Janssen